If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 9 of 9
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers
Objective
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Participants with Advanced Melanoma or Squamous Cell Head and Neck Cancer
Protocol No
SWOG-S2101
Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
Objective
Testing a narrower margin in surgery for patients with primary cutaneous melanoma
We are doing this study because we want to find out if this approach is better or worse than the usual approach for melanoma surgery. The usual approach is defined as care most people get for melanoma.
We are doing this study because we want to find out if this approach is better or worse than the usual approach for melanoma surgery. The usual approach is defined as care most people get for melanoma.
Protocol No
SWOG-S2015
Categories
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors
Objective
To assess the safety, tolerability, dose-limiting toxicities (DLTs), and determine the maximum tolerated dose of INBRX-106 as a single agent administered as an intravenous infusion and in combination with pembrolizumab.
Protocol No
INHIBRX-PH1-INBRX-106
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
Objective
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Protocol No
ECOG-EA6192
Categories
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases
Objective
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Protocol No
NRG-BN013
Categories
Cancer,
Other Skin,
Bladder,
Colorectal,
Cervix,
Other Gynecologic,
Breast Cancers,
Esophagus,
Prostate,
Larynx,
Other Gastrointestinal,
Esophagus,
Gynecologic Cancers,
Other Respiratory,
Melanoma, Skin,
Prostate and Urologic Cancers,
Pancreas/Liver,
Eye/Orbital Cancers,
Thoracic Cancers,
Lip, Oral Cavity and Pharynx,
Head and Neck Cancers,
Gastrointestinal Cancers,
Endocrine Cancers,
Skin Cancers,
Brain and Spine Cancers
The Role of Nodal Radiation Therapy in Sentinel Lymph Node Positive Melanoma
Objective
The role of nodal radiation therapy in sentinel lymph node positive melanoma
Protocol No
MDA-2020-0148
Categories
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Objective
A Phase 1/2 Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Protocol No
MIRATI-1719-001
Categories
Cancer,
Other Skin,
Thoracic Cancers,
Gynecologic Cancers,
Other Gastrointestinal,
Early Phase/Multiple Disease Site Cancers,
Lip, Oral Cavity and Pharynx,
Melanoma, Skin,
Esophagus,
Bladder,
Pancreas/Liver,
Prostate,
Skin Cancers,
Kidney,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Colorectal,
Gastrointestinal Cancers,
Sarcoma,
Breast Cancers
An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Objective
An Open-label, Multicenter Study of LY4050784 in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Protocol No
LOXO-J5M-OX-JOXA
Categories
Cancer,
Stomach,
Prostate,
Breast Cancers,
Other Skin,
Lip, Oral Cavity and Pharynx,
Larynx,
Ovary,
Head and Neck Cancers,
Thoracic Cancers,
Sarcoma,
Other Urologic,
Pancreas/Liver,
Cervix,
Gynecologic Cancers,
Esophagus,
Melanoma, Skin,
Bladder,
Gastrointestinal Cancers,
Prostate and Urologic Cancers,
Early Phase/Multiple Disease Site Cancers,
Skin Cancers
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
Objective
A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Categories
Cancer,
Lip, Oral Cavity and Pharynx,
Cervix,
Melanoma, Skin,
Skin Cancers,
Prostate and Urologic Cancers,
Breast Cancers,
Other Gastrointestinal,
Gynecologic Cancers,
Thoracic Cancers,
Pancreas/Liver,
Esophagus,
Colorectal,
Endocrine Cancers,
Gastrointestinal Cancers,
Sarcoma,
Larynx,
Brain and Spine Cancers,
Head and Neck Cancers